The first RSV vaccines were approved in the US in May last year. GSK’s Arexvy vaccine generated more than $1bn in sales in ...

Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

"Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I" was originally created and published by ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding.